Get started
NeuroMetrix, Inc.NeuroMetrix, Inc.NeuroMetrix, Inc.

NeuroMetrix, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

NURO trade ideas

$NURO The Rise Of Neurological Healthcare DevicesNeurological healthcare devices are no longer figments of fiction confined to the pages of Sci-fi novels. One of the most prominent producers of these neurological healthcare devices is NeuroMetrix, Inc. (NASDAQ: NURO), which is known for its Quell device that treats fibromyalgia and might become a viable treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN). That said, NURO stock is in a unique position because of Quell’s promising prospects which gives it a significant edge in the healthcare industry and might help it rebound from its earnings fall last quarter. NURO Fundamentals Following its Q1 report, NURO stock dropped 30% as a result of declining revenues due to its DPNCheck device’s sales dropping because of screening program cancellations – including some from its largest Medicare customer. However, that drop might be an overreaction since the company’s first and only FDA-approved device for treating fibromyalgia – Quell – provides it with a significant edge in the market. With this in mind, Quell has also shown promising results in treating CIPN in clinical studies which might open up a new market for NURO. Fibromyalgia Treatment Fibromyalgia is a chronic pain disorder that affects around 10 million people in the United States. People with fibromyalgia experience a constant stream of painful episodes that drastically decrease patients’ quality of life. It is for that reason that there is a lot of demand for better fibromyalgia treatments. Quell’s rise in popularity in the medical industry is due to that very reason as it fulfills a previously unmet need for more effective fibromyalgia treatments by stimulating sensory nerves. Quell was approved by the FDA in Q4 2022 and is showing impressive success since it has been prescribed 234 times by 92 physicians which indicates that Quell is gaining notoriety. Given its efficacy and the fact that it is the only device approved by the FDA for fibromyalgia treatment, it is likely going to experience a surge in sales as more physicians and healthcare providers familiarize themselves with Quell. Chemotherapy Induced Peripheral Neuropathy (CIPN) Not only does Quell treat fibromyalgia, but it has the potential to also treat CIPN – for which the company is currently performing clinical studies. CIPN is a medical term used to describe the damage done to the peripheral nerves as a result of chemotherapy, symptoms of which include loss of control over the extremities and bladder. Around 650 thousand cancer patients in the US receive chemotherapy annually of which 68% report CIPN in the first 3 months and 30% after 6 months. These figures illustrate a growing need for CIPN treatment, which could possibly be provided thanks to Quell. If Quell is approved for treating CIPN, the device could provide NURO with substantial revenues. Currently, NURO stock is in a phase 2 CIPN study consisting of 142 subjects. During the study, 50% of patients reported a reduction of systems for the active treatment as opposed to 30% who experienced the sham treatment. These results are positive since it means that there is a higher likelihood of Quell transitioning out of the pivotal trial phase and into the regulatory authorization phase. Liquidity As things stand, there is minimal risk of dilution associated with NURO stock since the company shared that it has enough liquidity for the coming year. With that in mind, NURO currently has an approved neuromodulator – Quell – in the market and also generates revenue from its diagnostic tool DPNCheck. Based on this, NURO has a steady stream of cash flow that could help it fund its pipeline without resorting to share offerings. At the same time, NURO has a low float of 7.6 million which is attractive for investors. In light of this, NURO stock could be poised to soar on any positive news – especially related to Quell. NURO Financials According to its Q1 2023 report, NURO’s assets decreased slightly QoQ from $24 million to $23 million and its cash balance was halved from $4.3 million to $2.3 million. On the other hand, its liabilities increased from $1.31 million to $1.59 million NURO’s revenues decreased YoY from $2.3 million to $1.7 million due to the reasons mentioned above. That said, its operating expenses also increased from $2.7 million to $2.9 million, which in turn caused net loss to increase from $958 thousand to $1.5 million. Technical Analysis NURO Stock is in a neutral trend and is trading in a sideways channel between $0.90 and $1.30 which the stock has broken through recently. Looking at the indicators, the stock is above its 200, 50, and 21 MA which are bullish indications. Meanwhile, the RSI is overbought at 73 and the MACD is bullish to the upside. As for the fundamentals, NURO’s Quell is the only FDA approved device for treating fibromyalgia which is likely to increase its revenue substantially. Additionally, it is in trials for CIPN treatment, which so far has produced favorable results. With the stock recently breaking through its sideways channel, investors could wait for a pullback as the RSI recalibrates before going long on NURO stock. NURO Forecast As things stand, NURO stock still has not recovered from its earnings drop. That said, NURO might be likely to make a full recovery due to the success of Quell. As the only device approved for fibromyalgia treatment, Quell could provide NURO with substantial revenues in the future, which may reflect on the NURO stock price eventually.
NASDAQ:NURO
by Penny_Stocks_Today
NURO | Time to Enter | LONGNeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ:NUROLong
by DivergenceSeeker
Spread triple top and BottomThe normal triple top has no gaps between the tops. The same philosophy applies in this pattern as in the triple top. In each case, the stock rises to a certain price level and is repelled two times. The third attempt at that price is successful by the stock’s moving through the level shown by a column of X’s exceeding the point of resistance. since the stock was repelled twice at that same level, there are apparently sell orders there. The reason is not important. What is important is that there are sellers at that particular level. The only way to know if demand can overtake the selling pressure is to see how the stock negotiates the level again. simply stated, if the stock is repelled again at this level of resistance, the sellers are still there. You need not know any more. If the stock exceeds that level, then demand has overcome the supply that previously caused it to reverse. This is why we always wait for a particular level to be exceeded before we make a long or short commitment in the stock. Friends, I conduct training in an individual format and in a limited number of students, since a large number will interfere with my trading! The training course includes : The Wyckoff Method Demark method VSA A trading method tailored to your psychotype Psychology of trading For details, write in a personal message I can also introduce you to my own unique indicators , of my own design Wykoff Zone (You determine the activity and zones of smart money and also gives buy and sell signals ) is a Demark indicator that has no analogues on the platform - since most of the indicator are far from the essence of the Demark technique and are too simplified , which violates the basics of the principle For investors, I can shift a 2-week lazy investor course where you can learn how to invest correctly and in which stocks + the tic-tac-toe method supplemented with your own developments taking into account the imbalance of supply and demand
NASDAQ:NUROEducation
by StudentWyckoff
$NURO is gonna fall todayPupm&Dump trading strategy idea. $NURO is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $25,95; stop-loss — $28,07; take-profit — $21,72. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:NUROShort
by KozakHlib
NURO Update Part 2Updating on day 2 of this NURO run as premarket highs have it making new multi-year highs. Looks like that highest-high fib line ( around 18.90) could be sticky as it was a failure point in 2018 and a heavy traffic area in 2017, which was support at that time. Let's see what happens here and whether the 17.70-17.80 area will hold as resistance or if there's enough gas left in the tank. I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to. **The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments. “We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.” Shai N. Gozani, M.D., Ph .D., President and CEO of NeuroMetrix Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .** Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NASDAQ:NURO
by PennyStocks101
NURO Fibbing Right Now Or New Highs Next?I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to. **The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments. “We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.” Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .** Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NASDAQ:NURO
by PennyStocks101
$NURO can rise in the next daysContextual immersion trading strategy idea. NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,01; stop-loss — $1,89. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:NUROLong
by KozakHlib